FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379981963> ?p ?o ?g. }

• W4379981963 endingPage "739" @default.
• W4379981963 startingPage "738" @default.
• W4379981963 abstract "Introduction: In clinical trials, treatment of chronic lymphocytic leukemia (CLL) with venetoclax (Ven) has shown promising efficacy and good tolerability.1,2 However, patients treated in clinical trial are often not representative in daily practice. Prospective real-world data on Ven usage are limited. Objective: We conduct a prospective non-interventional observational study assessing effectiveness, safety, and quality of life in relapsed/refractory patients (RR) treated with Ven in Austria, Germany, and Switzerland. The population enrolled is representative for patients treated with Ven according to local label.3 This report focuses on patients treated with Ven in combination with rituximab (R). Methods: Adult patients with CLL requiring therapy treated with Ven+R according to local label are eligible for the study. Patient’s visits are scheduled at the physician’s discretion and according to clinical practice. Study documentation is possible at baseline, weekly during ramp-up, monthly until the end of 6 months and 3-monthly afterwards up to a maximum of 3 years. Response assessment according to iwCLL criteria can be documented at the end of ramp-up, after 3, 12, and 24 months. Results: Until Nov 4th, 2022, 106 patients receiving VenR were enrolled, 105 with at least one dose of Ven (= safety population), for 87 treatment response had been documented at least once (= effectiveness population). Median age at therapy start was 74 years, 72.6% of patients were male, 76.4% had at least one comorbidity, most commonly cardiovascular (57.5%) and 73.6% received comedication. Patients were pre-treated with a median of 1 (range 1-10) line of therapy, e.g., chemo-immuno-therapy (CIT: 75.5%) or B-cell receptor inhibitors (34.9%). Del(17p), TP53 mutation, and presence of unmutated IGHV had been diagnosed in 23.6%, 24.5%, and 40.6%, respectively (excl. missing data: 28.7%, 30.6%, 69.4%). With a median observation time of 652 (range 14-1364) days, 93.3% of patients experienced at least one AE, 58.1% experienced CTCAE grade 3/4 AEs, SAEs were reported in 41.0%. Grade 5 AEs were reported in 10 patients, tumor lysis syndrome (TLS) in 12 patients (11.4%). The median for progression-free survival (PFS) and overall survival (OS) has not been reached, the 24-month estimates were 80.1% (PFS) and 84.1% (OS). The reported best overall response at 24 months was 88.5% (CR+CRi 59.8%; PR: 28.7%). Remissions continue to deepen with longer treatment duration. Conclusions: Under real-world conditions, VenR is used in elderly patients with comorbidities. The treatment was well tolerated. Most patients receive VenR in 2L of therapy after initial CIT. The response rate in patients presenting with high risk features, e.g., del(17p), TP53 mutation or unmutated IGHV, was high. Despite the advanced age of the enrolled patient population, PFS and OS estimates are comparable to pivotal phase III trial MURANO. The research was funded by: AbbVie sponsored this study and contributed to the design, study conduct. Keywords: molecular targeted therapies, ongoing trials Conflicts of interests pertinent to the abstract I. Schwaner Consultant or advisory role AbbVie, Amgen, AstraZeneca, BeiGene, Janssen, Roche, Servier. H. Hebart Consultant or advisory role AbbVie, AstraZeneca, BeiGene, Celgene, Janssen, and Roche C. Losem Consultant or advisory role AbbVie, Amgen T. Wolff Consultant or advisory role Novartis, Celgene, Roche, Bayer, Teva and Abbvie B. Schmidt Consultant or advisory role AbbVie, Incyte, Celgene, Novartis, Roche, Hexal, Biotest, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen und Amgen D. Rossi Consultant or advisory role AbbVie, AstraZeneca, Gilead, Janssen, Verastem, Roche, Cellestia C. Lehmann Employment or leadership position: employees of AbbVie and may own AbbVie stock J. Benzel Employment or leadership position: employees of AbbVie and may own AbbVie stock J. Huelsenbeck Employment or leadership position: employees of AbbVie and may own AbbVie stock P. Pichler Consultant or advisory role Amgen, Gilead, Janssen, Sanofi-Aventis, Takeda" @default.
• W4379981963 created "2023-06-10" @default.
• W4379981963 creator A5010466418 @default.
• W4379981963 creator A5015790909 @default.
• W4379981963 creator A5023612723 @default.
• W4379981963 creator A5028464891 @default.
• W4379981963 creator A5032226480 @default.
• W4379981963 creator A5044039643 @default.
• W4379981963 creator A5058629026 @default.
• W4379981963 creator A5068570608 @default.
• W4379981963 creator A5069901701 @default.
• W4379981963 creator A5083154064 @default.
• W4379981963 date "2023-06-01" @default.
• W4379981963 modified "2023-10-12" @default.
• W4379981963 title "SAFETY AND EFFECTIVENESS IN R/R CLL PATIENTS TREATED WITH VENETOCLAX IN COMBINATION WITH RITUXIMAB UNDER REAL‐WORLD CONDITIONS IN AUSTRIA, GERMANY, AND SWITZERLAND" @default.
• W4379981963 doi "https://doi.org/10.1002/hon.3165_590" @default.
• W4379981963 hasPublicationYear "2023" @default.
• W4379981963 type Work @default.
• W4379981963 citedByCount "0" @default.
• W4379981963 crossrefType "journal-article" @default.
• W4379981963 hasAuthorship W4379981963A5010466418 @default.
• W4379981963 hasAuthorship W4379981963A5015790909 @default.
• W4379981963 hasAuthorship W4379981963A5023612723 @default.
• W4379981963 hasAuthorship W4379981963A5028464891 @default.
• W4379981963 hasAuthorship W4379981963A5032226480 @default.
• W4379981963 hasAuthorship W4379981963A5044039643 @default.
• W4379981963 hasAuthorship W4379981963A5058629026 @default.
• W4379981963 hasAuthorship W4379981963A5068570608 @default.
• W4379981963 hasAuthorship W4379981963A5069901701 @default.
• W4379981963 hasAuthorship W4379981963A5083154064 @default.
• W4379981963 hasBestOaLocation W43799819631 @default.
• W4379981963 hasConcept C126322002 @default.
• W4379981963 hasConcept C141071460 @default.
• W4379981963 hasConcept C197934379 @default.
• W4379981963 hasConcept C2777938653 @default.
• W4379981963 hasConcept C2778375690 @default.
• W4379981963 hasConcept C2778461978 @default.
• W4379981963 hasConcept C2779338263 @default.
• W4379981963 hasConcept C2779675984 @default.
• W4379981963 hasConcept C2780653079 @default.
• W4379981963 hasConcept C2908647359 @default.
• W4379981963 hasConcept C38652104 @default.
• W4379981963 hasConcept C41008148 @default.
• W4379981963 hasConcept C71924100 @default.
• W4379981963 hasConcept C9583187 @default.
• W4379981963 hasConcept C99454951 @default.
• W4379981963 hasConceptScore W4379981963C126322002 @default.
• W4379981963 hasConceptScore W4379981963C141071460 @default.
• W4379981963 hasConceptScore W4379981963C197934379 @default.
• W4379981963 hasConceptScore W4379981963C2777938653 @default.
• W4379981963 hasConceptScore W4379981963C2778375690 @default.
• W4379981963 hasConceptScore W4379981963C2778461978 @default.
• W4379981963 hasConceptScore W4379981963C2779338263 @default.
• W4379981963 hasConceptScore W4379981963C2779675984 @default.
• W4379981963 hasConceptScore W4379981963C2780653079 @default.
• W4379981963 hasConceptScore W4379981963C2908647359 @default.
• W4379981963 hasConceptScore W4379981963C38652104 @default.
• W4379981963 hasConceptScore W4379981963C41008148 @default.
• W4379981963 hasConceptScore W4379981963C71924100 @default.
• W4379981963 hasConceptScore W4379981963C9583187 @default.
• W4379981963 hasConceptScore W4379981963C99454951 @default.
• W4379981963 hasIssue "S2" @default.
• W4379981963 hasLocation W43799819631 @default.
• W4379981963 hasOpenAccess W4379981963 @default.
• W4379981963 hasPrimaryLocation W43799819631 @default.
• W4379981963 hasRelatedWork W2087016115 @default.
• W4379981963 hasRelatedWork W2349164817 @default.
• W4379981963 hasRelatedWork W2584413057 @default.
• W4379981963 hasRelatedWork W2791038413 @default.
• W4379981963 hasRelatedWork W2892379175 @default.
• W4379981963 hasRelatedWork W3080900421 @default.
• W4379981963 hasRelatedWork W4234339317 @default.
• W4379981963 hasRelatedWork W4378175242 @default.
• W4379981963 hasRelatedWork W4384199484 @default.
• W4379981963 hasRelatedWork W4386270784 @default.
• W4379981963 hasVolume "41" @default.
• W4379981963 isParatext "false" @default.
• W4379981963 isRetracted "false" @default.
• W4379981963 workType "article" @default.